Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer

References

• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020. DOI:10.1038/s41575-020-0310-z.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73(1):170–185.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Tavolari S, et al. Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives. Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):441–452.
   PubMed Web of Science ®Google Scholar
• Jung SJ, Woo SM, Park HK, et al. Patterns of initial disease recurrence after resection of biliary tract cancer. Oncology. 2012;83(2):83–90.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Brandi G. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021 Feb 11:1–8. DOI:10.1080/17474124.2021.1890031.
   Web of Science ®Google Scholar
• Forner A, Vidili G, Rengo M, et al., Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl1): 98–107.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Khan SA, Hallemeier CL, et al., Cholangiocarcinoma ‐ evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2): 95‐111.
   PubMed Web of Science ®Google Scholar
• Sahin IH, Tan E, Kim R. Regorafenib, an investigational agent for the treatment of cholangiocarcinoma. Expert Opin Investig Drugs. 2020 Dec;30:1–9.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Brandi G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Rev Gastroenterol Hepatol. 2020 Dec;18:1–3.
   Web of Science ®Google Scholar
• Malenica I, Donadon M, Lleo A. Molecular and immunological characterization of biliary tract cancers: a paradigm shift towards a personalized medicine. Cancers (Basel). 2020;12(8):2190.
   Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019 Jun 1;5(6):824–830.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Lamarca Á, et al. ABC-06 | a randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J Clin Oncol. 2019;37(28):2571–2580.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Kamgar M, Mahipal A. Targeted therapies in advanced biliary tract cancer: an evolving paradigm. Cancers (Basel). 2020 Jul 24;12(8):2039.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Bridgewater J, Gores GJ, et al. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353–363.
   PubMed Web of Science ®Google Scholar
• Massa A, Varamo C, Vita F, et al. Evolution of the experimental models of cholangiocarcinoma. Cancers (Basel). 2020;12(E):2308.
   Web of Science ®Google Scholar
• Sipra QUAR, Shroff R. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs. Expert Opin Investig Drugs. 2020 Nov;23:1–4.
   Web of Science ®Google Scholar
• Botrus G, Raman P, Oliver T, et al. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. Expert Opin Investig Drugs. 2021 Jan;4:1–8.
   Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin Investig Drugs. 2020;14:1-8.DOI:10.1080/13543784.2021.1837774.
   Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–684.
   Web of Science ®Google Scholar
• Baiocchi L, Sato K, Ekser B, et al. Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Expert Opin Investig Drugs. 2020 Dec;8:1–11.
   Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al., IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020 May 14;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• Massari F, Mollica V, Rizzo A, et al. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020 Oct;19(10):1329–1338.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Wu Q, Jiang L, Li SC, et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin. 2021;42(1):1-9. DOI:10.1038/s41401-020-0366-x. Epub 2020 Mar 9.
   Web of Science ®Google Scholar
• Ricci AD, Rizzo A, Brandi G. Immunotherapy in biliary tract cancer: worthy of a second look. Cancer Control. 2020;27(3):107327482094804.
   Web of Science ®Google Scholar
• Valle JW, Lamarca A, Goyal L, et al., New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9): 10‐8290.
   PubMed Web of Science ®Google Scholar
• Oneda E, Abu Hilal M, Zaniboni A. Biliary tract cancer: current medical treatment strategies. Cancers (Basel). 2020;12(5):1237.
   PubMed Web of Science ®Google Scholar
• Kim R, Coppola D, Wang E, et al. Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma. Oncotarget. 2018;9(34):23366–23372.
   PubMedGoogle Scholar
• Ricci AD, Rizzo A, Brandi G. The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box? ESMO Open. 2020;5(5):e001042.
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Martin-Liberal J, Calvo E, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). Oncologist. 2018;23(12):1407–e136.
   PubMed Web of Science ®Google Scholar
• Hilmi M, Vienot A, Rousseau B, et al. Immune therapy for liver cancers. Cancers (Basel). 2019;12(1):77.
   Web of Science ®Google Scholar
• Xie C, McGrath NA, Monge Bonilla C, et al. Systemic treatment options for advanced biliary tract carcinoma. J Gastroenterol. 2020 Oct;55(10):944–957.
   PubMed Web of Science ®Google Scholar
• Haber PK, Sia D. Translating cancer genomics for precision oncology in biliary tract cancers. Discov Med. 2019 Nov-Dec;28(155):255–265.
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020 Oct 15;147(8):2190–2198.
   PubMed Web of Science ®Google Scholar
• Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020 Jun 1;6(6):888–894.
   PubMed Web of Science ®Google Scholar
• Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611–621.
   PubMed Web of Science ®Google Scholar
• Song X, Hu Y, Li Y, et al. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 2020 Oct 7;5(1):230.
   PubMed Web of Science ®Google Scholar
• Klein O, Kee D, Nagrial A, et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol. 2020;6(9):1405.
   Web of Science ®Google Scholar
• Sahai V, Griffith KA, Beg MS, et al. A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01). J Clin Oncol. 2020;38(15_suppl):4582.
   Web of Science ®Google Scholar
• Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2016;23(8):2610–2617.
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol. 2019;10(4):652–662.
   PubMed Web of Science ®Google Scholar
• Tan S, Liu K, Chai Y, et al. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2018;9(1):135–139.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052–1062.
   PubMed Web of Science ®Google Scholar
• Lee HT, Lee JY, Lim H, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep. 2017;7(1):5532.
   PubMed Web of Science ®Google Scholar
• Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119–3125.
   PubMed Web of Science ®Google Scholar
• Alvarez-Argote J, Dasanu CA. Durvalumab in cancer medicine: a comprehensive review. Expert Opin Biol Ther. 2019 Sep;19(9):927–935.
   PubMed Web of Science ®Google Scholar
• Picardo SL, Doi J, Hansen AR. Structure and optimization of checkpoint inhibitors. Cancers (Basel). 2019;12(1):38.
   Web of Science ®Google Scholar
• Murakami S. Durvalumab for the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther. 2019 Dec;19(12):1009–1016.
   PubMed Web of Science ®Google Scholar
• Lavaud P, Hamilou Z, Loriot Y, et al. Durvalumab in urothelial cancers. Expert Rev Anticancer Ther. 2018 Apr;18(4):311–318.
   PubMed Web of Science ®Google Scholar
• Muñoz-Unceta N, Burgueño I, Jiménez E, et al. Durvalumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2018 Oct;11(10):1758835918804151.
   Web of Science ®Google Scholar
• Mezquita L, Planchard D. Durvalumab in non-small-cell lung cancer patients: current developments. Future Oncol. 2018 Feb;14(3):205–222.
   PubMed Web of Science ®Google Scholar
• Ioka T, Ueno M, Oh DY, et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J Clin Oncol. 2019;37(4_suppl):387.
   Web of Science ®Google Scholar
• Floudas CS, Xie C, Brar G, et al. Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC). J Clin Oncol. 2019;37(4_suppl):336.
   PubMed Web of Science ®Google Scholar
• Ko EC, Formenti SC. Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality. Int J Radiat Biol. 2019 Jul;95(7):936–939.
   PubMed Web of Science ®Google Scholar
• Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett. 2018 Apr;10(419):210–221.
   Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015 May;3(5):436–443.
   PubMed Web of Science ®Google Scholar
• Oh DY, Lee KH, Lee DW, et al. Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC). J Clin Oncol. 2020;38(15_suppl):4520.
   Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. Future Oncol. 2021 Jan 29;17(7):755–757.
   Web of Science ®Google Scholar
• Shafique MR, Robinson LA, Antonia S. Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Cancer Manag Res. 2018 May;1(10):931–940.
   Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al., CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929–1939.
   PubMed Web of Science ®Google Scholar
• Yang H, Shen K, Zhu C, et al. Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. Drug Des Devel Ther. 2018 Jul 6;12:2085–2096.
   PubMed Web of Science ®Google Scholar
• Khunger M, Jain P, Rakshit S, et al. Safety and efficacy of PD-1/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2018 May;19(3):e335–e348.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017Nov16;377(20):1919–1929.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al., PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018 Dec 13;379(24):2342–2350.
   PubMed Web of Science ®Google Scholar
• Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017;3(9):e172411.
   PubMed Web of Science ®Google Scholar
• Ahn S, Lee J, Shin DW, et al. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Sci Rep. 2020;10(12348). DOI:10.1038/s41598-020-69366-4
   Web of Science ®Google Scholar
• Lim YJ, Koh J, Kim K, et al. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer under-going surgery plus adjuvant chemoradiotherapy. Radiother Oncol. 2015;117(1):165–170.
   PubMed Web of Science ®Google Scholar
• Arora S, Velichinskii R, Lesh RW, et al. Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors. Adv Ther. 2019 Oct;36(10):2638–2678.
   PubMed Web of Science ®Google Scholar
• Morizane C, Ueno M, Ikeda M, et al. New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol. 2018 Aug 1;48(8):703–711.
   PubMed Web of Science ®Google Scholar
• Neyaz A, Husain N, Kumari S, et al. Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy. Histopathology. 2018 Oct;73(4):622–633.
   PubMed Web of Science ®Google Scholar
• Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol. 2018 Jul;13(10):1758835918786658.
   Web of Science ®Google Scholar
• Spizzo G, Puccini A, Xiu J, et al. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open. 2020;5(3):e000682.
   Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Biliary tract cancer: state of the art and potential role of DNA damage repair. Cancer Treat Rev. 2018 Nov;70:168–177.
   PubMed Web of Science ®Google Scholar
• Ahn DH, Bekaii-Saab T. Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors. Chin Clin Oncol. 2020 Feb;9(1):6.
   PubMed Web of Science ®Google Scholar
• Ding L, Chen F, Phimister EG. Predicting tumor response to PD-1 blockade. N Engl J Med. 2019 Aug 1;381(5):477–479.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086.
   PubMed Web of Science ®Google Scholar
• Wang J, Ilyas S. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Investig Drugs. 2020 Dec;28:1–10.
   Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021 Jan;8:1–10.
   Google Scholar
• Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers (Basel). 2021 Feb 1;13(3):558.
   PubMed Web of Science ®Google Scholar
• Cho BC, Daste A, Ravaud A, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer. 2020 Jul;8(2):e000664.
   PubMed Web of Science ®Google Scholar